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Head and neck squamous cell carcinoma (HNSCC) has a high recurrence and
metastatic rate with an unknown mechanism of cancer spread. Tumor inflammation
is the most critical processes of cancer onset, growth, and metastasis. We hypothesize
that the release of extracellular vesicles (EVs) by tumor endothelial cells (TECs) induce
reprogramming of immune cells as well as stromal cells to create an immunosuppressive
microenvironment that favor tumor spread. We call this mechanism as non-metastatic
contagious carcinogenesis. Extracellular vesicles were collected from primary HNSCC-
derived endothelial cells (TEC-EV) and were used for stimulation of peripheral blood
mononuclear cells (PBMCs) and primary adipose mesenchymal stem cells (ASCs).
Regulation of ASC gene expression was investigated by RNA sequencing and protein
array. PBMC, stimulated with TEC-EV, were analyzed by enzyme-linked immunosorbent
assay and fluorescence-activated cell sorting. We validated in vitro the effects of TEC-
EV on ASCs or PBMC by measuring invasion, adhesion, and proliferation. We found
and confirmed that TEC-EV were able to change ASC inflammatory gene expression
signature within 24–48 h. TEC-EV were also able to enhance the secretion of TGF-β1
and IL-10 by PBMC and to increase T regulatory cell (Treg) expansion. TEC-EV carry
specific proteins and RNAs that are responsible for Treg differentiation and immune
suppression. ASCs and PBMC, treated with TEC-EV, enhanced proliferation, adhesion
of tumor cells, and their invasion. These data indicate that TEC-EV exhibit a mechanism
of non-metastatic contagious carcinogenesis that regulates tumor microenvironment
and reprograms immune cells to sustain tumor growth and progression.
Keywords: extracellular vesicles, tumor endothelial cells, tumor immune editing, T regulatory (T reg) cells, head
and neck cancer
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INTRODUCTION
Tumor angiogenesis, the formation of new blood vessels within a
tumor, is one of the crucial steps of tumor growth and progression
(Folkman, 1985). TECs are the cells lining the tumor-associated
blood vessels (Dudley, 2012). Recent data suggest that TEC play
a critical role in tumor growth and metastasis (Osawa et al.,
2013; Yadav et al., 2015), and show characteristics of cancer
stem cells (Dudley et al., 2008). TEC could regulate tumor
microenvironment since they have direct contact with blood
cells and vessel stromal cells. This regulation is mediated via
production of increased levels of growth factors and cytokines,
as well as via release of EV. EV are membrane vesicles containing
a specific set of proteins, lipids, and nucleic acids, which could
incorporate into recipient cells via cell surface receptors and
regulate their gene expression (Quesenberry et al., 2015).
Extracellular vesicles are essential regulators of inflammation
and angiogenesis (Baruah and Wary, 2019). Cancer requirement
of inflammation is now widely described for almost all types of
cancer since immune cells infiltrate tumor stroma and contribute
to cancer development. EV secreted by tumor cells were
shown to play an essential role in tumor niche establishment,
metastasis (Hoshino et al., 2015), and regulation of immune
reaction and inflammation (Ye et al., 2014; Grange et al.,
2015). EV could activate immune cells by binding their surface
receptors, such as MHC class I and II, CD47, TLR4, and others
(Robbins et al., 2016).
Extracellular vesicles stimulate immune cells to express
cytokines and growth factors critical for angiogenesis, TGF-
β1, TNF-α, IL-6, and others (Roma-Rodrigues et al., 2014).
Therefore, inflammation and angiogenesis are interdependent;
moreover, those processes share participating immune cells
and signaling pathways (Mamlouk and Wielockx, 2013;
Szade et al., 2015).
Head and neck squamous cell carcinoma is the fifth most
common cancer worldwide and has a high recurrence and
metastasis rate (Argiris et al., 2008). It was shown that
EV from HNSCC cells could inhibit T-cell proliferation and
differentiation of pro-inflammatory cells Th1 and Th17 (Ye et al.,
2014). HNSCC-derived EV are enriched in tumor antigens and
potentially promote tumor progression (Principe et al., 2013).
At present, limited information is available on the cellular and
Abbreviations: ACTB, actin beta 1; ASCs, adipose stem cells; CD14, cluster
of differentiation 14; CD31, cluster of differentiation 31; CD47, cluster
of differentiation 47; CD73, cluster of differentiation 73; CD90, cluster of
differentiation 90; CD105, cluster of differentiation 105; CD163, cluster of
differentiation 163; CD206, cluster of differentiation 206; CM, conditioned
medium; Ctr, control; DMEM, Dulbecco’s modified Eagle medium; DMSO,
dimethyl sulfoxide; ELISA, enzyme-linked immunosorbent assay; EVs,
extracellular vesicles; FACS, fluorescence-activated cell sorting; FBS, fetal bovine
serum; HLA, human leukocyte antigen; HMEC, human dermal microvascular
endothelium; HNSCC, head and neck squamous cell carcinoma; IFN-γ, interferon
gamma; IL-6, interleukin 6; IL-10, interleukin 10; lncRNA, long non-coding RNA;
MALAT1, metastasis associated lung adenocarcinoma transcript 1; MHC, major
histocompatibility complex; PBMC, peripheral blood mononuclear cell; PBS,
phosphate-buffered saline; RNA, ribonucleic acid; RT-PCR, reverse transcription
polymerase chain reaction; TECs, tumor endothelial cells; TGF-β1, transforming
growth factor beta-1; Th1, T helper type 1; Th17, T helper type 17; TLR4, toll-like
receptor 4; TNF-α, tumor necrosis factor alpha; Treg, T regulatory cells; Trtm,
treatment; VEGF, vascular endothelial growth factor.
molecular functions of TEC from HNSCC and EV released
by those cells (Rodriguez Zorrilla et al., 2019; Xie et al.,
2019). Studying the TEC-EV molecular composition and specific
functions in tumor development can define novel mechanisms
of cancer immune editing, help developing novel therapeutic
targets, and determine diagnostic signatures to be used for non-
invasive liquid biopsies.
Here we investigated the role of EV released by TEC from
HNSCC in the reprogramming of non-tumor cells, such as
PBMCs or mesenchymal stem cells from adipose tissue (ASCs).
Those cells underwent induction and contributed to tumor
development by the secretion of growth factors and cytokines.
This study characterized the regulation of the immune response
by TEC-EV and showed the pro-tumorigenic functions of non-
tumor cells after induction with TEC-EV.
MATERIALS AND METHODS
Ethics Approval and Consent to
Participate
Overall, we received the ethics approval for the isolation of
human cells, such as TEC and tumor cells from HNSCC
patients, as well as ASC from non-neoplastic patients. HNSCC
tissues were isolated under approved protocol from the Ethics
Committee of A.O.U. Città della Salute e della Scienza di Torino,
Turin, Italy (CS2/1255 – Protocol number 0050416, May 16,
2019). ASC isolation was approved by the Ethics Committee
of A.O.U. Città della Salute e della Scienza di Torino, Turin,
Italy (CS/100 – Protocol number 12175, February 4, 2014).
Adipose tissue was obtained from patients of non-neoplastic
elective abdominal surgery. Informed consent was obtained from
all patients according to the Helsinki Declaration. Laboratory
researchers had no direct contact with the participants in the
present study (patients’ anonymity was guaranteed).
TEC Isolation
TEC were isolated from tumor tissue samples of HNSCC patients
(stage IV). Specimens were finely minced and digested by
incubation in DMEM medium with 220 U/mL collagenase I
(Sigma) for 1 h at 37◦C. After washings the cells in DMEM
with 10% FBS (Lonza), endothelial cells were isolated from this
filtered cells suspension using magnetic beads conjugated with
anti-CD105 Ab (Supplementary Table S1) from magnetic cell-
sorting MACS system (Miltenyi Biotech). TECs were grown in
the complete EndoGro medium (Millipore) supplemented with
2% FBS, as previously described (Grange et al., 2006). Expression
of CD31 by the isolated cells was confirmed by FACS analysis on
the passages #1 and #4. TEC were used at 8–18 passages. TEC
were functionally evaluated to form vessel-like structures at 4, 8,
and 18 passages (see below).
Tumor cells were isolated from the specimens of four HNSCC
male patients (mean age 62 ± 5) without sorting and cultured
in MSCBM complete medium (Lonza). Tumor cells do not
form vessel-like structures on Matrigel and have fibroblast-like
morphology. The cells were allowed to undergo 8–18 passages
before being used in the experiments.
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ASC Isolation
Adipose mesenchymal stem cells exhibit diverse inflammatory
and secretory features depending on patient’ age, health,
metabolism, and body size (Efimenko et al., 2014; Louwen et al.,
2018). We used ASCs isolated from subcutaneous abdominal
tissue of non-obese five male patients, submitted to non-
neoplastic elective abdominal surgery (mean age 60 ± 8). Those
adipose tissues were washed in sterile PBS and were minced
into pieces of 2 mm in diameter. ASCs were isolated by enzyme
digestion with 220 U/mL collagenase I type (Worthington
Biochemical), and 40 U/mL dispase (Invitrogen Corporation) in
DMEM, FBS deprived, and containing 100 units/ml penicillin,
0.1 mg/ml streptomycin, and 0.25 µg/ml amphotericin B
(antibiotic/antimycotic solution, Sigma). The tissue was digested
at 37◦C for 30 min with constant mixing. Enzyme activity
was neutralized with an equal volume of DMEM, containing
10% FBS. The digested suspension was centrifuged at 900 g
for 10 min to obtain a high-density stromal vascular fraction
pellet. The cell pellet was resuspended in MSCBM complete
medium (Lonza) and cultured at 37◦C in 5% CO2 incubator.
After 2 days, the medium with detached cells was changed, and
the adherent cells were cultivated until 100% confluence. ASC
characterization was performed by FACS analysis for the positive
expression of mesenchymal markers (CD105, CD73, CD90), and
negative expression of hematopoietic markers (CD31) and by
differentiation into adipogenic, osteogenic, and chondrogenic
phenotypes as previously described (Kalinina et al., 2015). For our
experiments, we used cells after 2–8 passages.
PBMC Isolation
The fresh PBMC was isolated from 15 healthy donors. Their
heparinized blood samples were used for the density gradient
centrifugation. PBMC were seeded in 6 well plates at a density
of 10× 106 cells per well in 2 ml of serum-free AIM V medium.
TEC-EV Isolation
To isolate EV from TEC, TEC were washed with FBS-deprived
DMEM and cultured in this medium for 18 h. The obtained
conditioned medium was centrifuged for 30 min at 3000 g
to remove cell debris and then filtered using 0.22 µm filters
(MillexGP). The supernatants were then ultracentrifuged for 3 h
at 100,000 g and 4◦C using the Beckman Coulter Optima L-100K
Ultracentrifuge with the rotor type 45 Ti 45000RPM. Minimum
of 67 ml of conditioned medium was used for ultracentrifugation
(maximum volume for the tubes). From this volume we extracted
0.5–2 × 1011 EV. The EV pellet was resuspended in DMEM
supplemented with 1% of dimethyl sulfoxide (DMSO) then
stored at−80◦C until further use.
ASC Stimulation With TEC-EV
To stimulate ASC with TEC-EV, we changed the complete growth
medium of ASC culture to FBS-deprived DMEM. We added
TEC-EV to the ASC culture to obtain the final concentration
10 × 103 EV/cell. ASC were incubated with TEC-EV for 24 or
48 h to obtain ASCind. As a control, ASC were incubated with
the equal volume of DMEM with 1% DMSO for 0, 24, or 48 h.
After incubation, the cells were harvested, lysed by QIAzol Lysis
Reagent and used for RNA isolation by RNAeasy kit (Qiagen),
following manufacturer’s instructions.
EV Isolation From Stimulated and
Non-stimulated ASC
ASCind (stimulated for 24 h with TEC-EV) were used for
isolation of their EV (ASCind-EV). Non-stimulated ASC were
used for control EV isolation (ASC-EV). After 24 h-incubation
with or without TEC-V, the growth medium of ASC was changed
to FBS-deprived DMEM for the additional 24 h. We isolated
EV from ASC conditioned medium as described for TEC-EV.
From one ultracentrifuge tube (67 ml of conditioned medium)
we extracted 1–5× 1010 EV.
PBMC Stimulation With EV
To stimulate PBMC with different EV (TEC-EV, ASC-EV, and
ASCind-EV), we added EV to PBMC in the concentration of
1 × 103 EV/cell for 48 h. After 48 h of incubation, the cultured
PBMC and conditioned media were harvested for FACS, RT-PCR,
and ELISA. For the T regulatory cell (Tregs) detection, PBMC
were analyzed 5 days after incubation with EV.
PBMC Consumption of EV
To demonstrate the intake of TEC-EV by PBMC, TEC-EV were
labeled with PKH26GL green fluorescent cell linker (Sigma) dye
for 30 min at 37◦C and then washed and ultracentrifuged at
100,000 g for 1 h at 4◦C. These labeled EV were added to PBMCs
(1× 103 EV/cell) for different times (10, 30 min, 1, 3, or 24 h). The
consumption of EV by PBMCs was evaluated by FACS (CytoFlex,
Beckman Coulter).
Vessel-Like Formation Assay
To verify the endothelial origin of TEC (donor cells, Table 1),
or measure the angiogenesis (recipient cells II, Table 1), we
have completed the vessel-like formation assay. For that, we
seeded the cells onto Matrigel-coated wells in a 24-well plate
(25 × 103 cells per well), and cultured TEC in DMEM medium
without FBS. In case of recipient cells II, 50% of the medium
was replaced by the conditioned medium (CM) from the control
PBMC or PBMCind. After incubation for 6 h, phase-contrast
images (magnification,× 100) were recorded, and the total length
of the network structures was measured using LAS software
(Leica). In the case of recipient cells II, the total length per field
was calculated in five random fields and expressed relative to CM
PBMC control. Data were expressed as mean± SEM.
Adhesion Assay
In this experiment, we measured PBMC or tumor cells adhesion
on the endothelium. As a source of endothelial cells, we
used HMEC (ATCC, PCS-110-010) cultured in EBM complete
medium (Lonza). During the adhesion assay, all cell types
(PBMC, endothelial cells, and tumor cells) were stimulated by
the same EV to imitate the physiological conditions of EV
circulation in the tumor blood vessels. HMEC seeded in 24-
well plate were allowed to grow until 100% confluence. Those
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TABLE 1 | Scheme of the study.
In gray columns – cells used for the study, in white – EV (or conditioned
media from PBMC). In bold – samples’ abbreviation used in text, in italic – methods
for molecular composition analysis used for the sample.
100% confluent HMECs were stimulated with control ASC-EV
or ASCind-EV in concentration 10 × 103 EV/cell overnight. At
the same time, PBMC or tumor cells were stimulated with the
same EV (in the concentration 10 × 103 EV/cell or 1 × 103
EV/cell for tumor cells or PBMC respectively). Next day, tumor
cells and PBMC were labeled with PKH26GL red fluorescent cell
linker (Sigma) according the manufacturer’s instructions. Labeled
PBMC (2 × 105 cells) or tumor cells (1 × 103) resuspended
in 0.5 ml of EBM complete medium were added to each well
of confluent and stimulated HMEC for 1 h incubation at 37◦C.
The non-adherent cells were removed by supernatant aspiration
and two additional washing steps with PBS. Adherent cells
were counted by digital analysis (Leica application suite V4.9).
Four independent experiments were performed in duplicates; the
results are expressed as mean of cells counted in 10 fields. The
non-stimulated cells (HMEC, PBMC, or tumor cells) were used
as negative controls.
Tumor Cell Proliferation
The proliferation of tumor cells was measured by BrdU
incorporation using Cell Proliferation ELISA BrdU
(colorimetric) kit (Roche, #11647229001) according to the
manufacturer’s instructions. Tumor cells were cultured in
DMEM deprived FBS and were stimulated by 50% diluted
conditioned medium from control PBMC or PBMCind. Tumor
cells were stimulated with such medium for 72 h.
Tumor Cell Invasion
The effect of ASC-EV on tumor cell invasion was detected by
the Transwell assay (COSTAR transwell, Corning Incorporated).
Tumor cells were resuspended in DMEM (serum-free) and
seeded into the upper compartment of an invasion chamber
(50 × 103 cells per well) containing a polycarbonate membrane
with an 8 µm pore size, which was coated with a layer Matrigel
(MatrigelTM, Becton Dickinson). ASC-EV or ASCind-EV were
added to the cells into the concentration 5× 108 EV/well. DMEM
with 10% of FBS was used as the attractant and added to the
bottom well. After 24 h of incubation, the invasive cells migrated
through the Matrigel to the bottom side of the membrane. The
migrated cells were stained with Mayer dye and counted. Every
experiment was repeated six times.
RNA Sequencing and Analysis of TEC-EV
Four TEC-EV samples were collected from the same TEC culture
on different cell passages and were used for RNA sequencing
using Lexogen1 service (Vienna, Austria). From 1 × 1011 of EV
was extracted around 30 µg of RNA. The service included the
comparison of RNA carried by TEC-EV with RNA carried by
ASC-EV by DeSeq2. The top 1000 up-regulated genes in TEC-
EV relative to ASC-EV (padj < 0.1) were used in the Panther
classification system2 for functional clustering.
RNA Sequencing of ASC Stimulated With
TEC-EV
RNA from treated and non-treated cells was extracted using
the mirVana miRNA Isolation Kit (Ambion, Forster City, CA,
United States). RNA sequencing was performed, as previously
described (Guo et al., 2017). Briefly, samples were required
to achieve an RNA Integrity Number (RIN) of at least 7.0.
A stranded RNA library was prepared using the Illumina
TruSeq stranded total RNA seq poly A + Gold kit (San Diego,
CA, United States), and then ribosomal RNA reduction was
performed from 400 ng of total RNA and purified with AMPure
XP magnetic beads.
Sequencing was performed using the HiSeq 2500 platform
sequencer (Illumina) and the TruSeq Cluster Kit, resulting in
approximately 80 million paired reads per sample. Next, the
RNA sequencing data were normalized based on the version 2
protocols developed by TCGA (Cancer Genome Atlas Network,
2015). The alignment was performed using MapSplice2 version
2.0.1.9 (Wang et al., 2010) to the GRCh37/hg19 genome
assembly. Gene expression values were quantified from RNA
sequencing data using RSEM version 1.2.9 (Li and Dewey,
2011) and upper quantile normalized. We found patterns on
this data by performing CoGAPS analysis on log transformed,
upper quantile normalized data (Fertig et al., 2010). This analysis
identified five patterns in the dataset, which were associated with
biological pathways by applying the CoGAPS gene set statistic
to Hallmark pathways (Liberzon et al., 2015) in MSigDB version
5.2. CoGAPS patterns are visualized by creating a heatmap of the
gene expression values for patternMarker genes that are uniquely
associated with each process (Stein-O’Brien et al., 2018).
Protein Array of EV
Protein composition of EV was identified by AAH-BGL-100004
Human L1000, Glass Slide array (RayBiotech). To extract protein
peptides, EV were lysed by 2x Cell Lysis Buffer (RayBiotech,
Inc.) and ultrasonicated 30 s at 4◦C (Microson Ultrasonic cell
disruptor; 47 kHz frequency and 185 Watt peak power). The
protein concentration was measured by BCA Protein Assay Kit
(Thermo Fisher). One µg of total protein was used for the
1www.lexogen.com
2http://www.pantherdb.org
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protein array according to manufacturer instructions. This array
provides detection of 1000 secreted proteins. For each set of EV,
we performed two technical repeats. Only proteins, consistently
detected in both replicates were used for functional clustering by
Panther classification system2.
Real-Time PCR Analysis
Total RNA from stimulated and non-stimulated PBMC, and from
EV released by ASC controls and ASCind, was extracted using
RNAeasy kit (Qiagen). Approximately 200 ng of RNA was reverse
transcribed into complementary DNA (cDNA) using miScript II
RT Kit (Qiagen) according to manufacturer’s protocol.
The analysis of the TGF-β1 and MALAT1 RNA expression,
as well as the expression of endogenous controls, ACTB
and 18S RNA, was performed using miScript SYBR
Green PCR kit (Qiagen). Specific primers for RT-PCR
(TGF-β1 forward CTAATGGTGGAAACCCACAACG,
reverse TATCGCCAGGAATTGTTGCTG; MALAT1 forw
ard CCCCTGGGCTTCTCTTAACA, reverse GCTAGATCAAA
AGGCACGGG; ACTB forward CATGTACGTTGCTATCCA
GGC, reverse CTCCTTAATGTCACGCACGAT, 18S RNA
forward AGAAACGGCTACCACATCCA, reverse CCC
TCCAATGGATCCTCGTT) were obtained from primer
bank3. Used real-time cycler conditions were following: PCR
initial activation step 15 min 95◦C; 40 steps of Denaturation
(94◦C, 15 s), Annealing (60◦C, 15 s), Extension (72◦C, 15 s);
fluorescence data collection after Extention of every cycle;
melting curve data between 60 and 95◦C. The RT-PCR was
performed on the QuantStudio 12K Flex real-time PCR
instrument (Applied Biosystems). The differential expression
analysis was performed using Expression Suite Software (Thermo
Fisher), using endogenous controls.
Fluorescence-Activated Cell Sorting
Fluorescence-activated cell sorting was used to define surface
protein markers on cells and EV. A pool of approximately
5 × 1010 cells or EV dissolved in 100 µl was incubated
with the particular antibody (Supplementary Table S1) for
30 min at room temperature. Then the final volume was
increased until 300 µl and FACS analysis was performed
using CytoFlex from Beckman Coulter. To detect EV we
used Violet Side Scatter (VSSC) that permit to detect even
smaller vesicles, as the refraction index of EVs is inversely
proportional to the size of the vesicle. We were able to select
the population of EV using CD63, CD81, and Annexin V as
positive controls. The median fluorescence intensity (MFI) was
corrected for background and gated based on their respective
fluorescence intensity as per manufacturer’s instructions. The
FITC, PerCP, or PE non-immune isotypic IgG were used as a
negative control.
ELISA Assay
ELISA assay was performed using DuoSet R© ELISA Development
Systems (R&D Systems) according to manufacturer instructions.
Briefly, the suspension of EV or cells was mixed with RIPA
3https://pga.mgh.harvard.edu/primerbank/
buffer and ultrasonicated. Then, 30 µg of total protein was
used for ELISA. TEC-EV were analyzed using kits specific to
IGF1, IL-1β, TGF-β1, and VEGF. PBMC or tumor cells were
analyzed using kits specific to IFN-γ, IL-6, IL-10, TGF-β1, TNF-
α, and VEGF.
Statistical Analysis
All reported p-values were calculated using pair-wise Student’s
t-test, comparing a condition of interest with its corresponding
control. p-Value < 0.05 was considered as significant.
RESULTS
The Study Flow
We performed two rounds of EV collection and used them
for stimulation of the recipient cells, as described in Table 1.
The study was started from the isolation of the TEC (donor
cells) and TEC-EV collection and characterization. TEC-EV were
analyzed by RNA sequencing, protein array, FACS, and ELISA
and were used for stimulation of two types of recipient cells I
(ASCs and PBMC). ASCs induced with TEC-EV (ASCind) were
analyzed by RNA sequencing at 24 and 48 h after the stimulation.
Non-stimulated control ASCs and TEC were also analyzed by
RNA sequencing for comparative analysis. PBMC stimulated
with TEC-EV (PBMCind) were analyzed by ELISA and FACS to
demonstrate activation and differentiation. At the second round,
control ASCs or ASCind were used for EV collection (ASC-EV
or ASCind-EV), which were used for stimulation of the recipient
cells II (tumor cells or PBMC).
EV Characterization
TEC-EV, ASC-EV, and ASCind-EV were analyzed using
Nanoparticle Tracking Analysis (Malvern Instruments, Ltd.) and
transmission electron microscopy. Mean size of EV evaluated
by electron microscopy was 90 nm (± 20); we did not detected
vesicles bigger than 100 nm o smaller than 30 nm. According
to Western blot all types of EV expressed CD63 and CD81
exosome markers but not endoplasmic reticulum calnexin
(Supplementary Figure S1).
Protein and RNA Composition of TEC-EV
To study the molecular composition of TEC-EV, we ran
RNA sequencing and protein array on TEC-EV. Analysis of
RNA sequencing of TEC-EV revealed that TEC-EV contained
mRNA from inflammation, interleukin signaling, TGF-β1,
and T and B cell activation pathways (Figure 1, left).
According to RNA sequencing data TEC-EV are enriched
with TGF-β1 mRNA and long non-coding RNA MALAT1.
TGF-β1 is a mediator of immunosuppression and Treg
differentiation (Taylor et al., 2006; Konkel et al., 2017), while
the MALAT1 was described as a downstream mediator of
TGF-β1 effect in immunosuppression (Yang et al., 2016;
Masoumi et al., 2019).
Analysis of TEC-EV proteins showed enrichment of similar
signaling pathways relevant to inflammation (Figure 1, right).
Comparison of gene lists, revealed by RNA sequencing and
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FIGURE 1 | RNA and protein composition of TEC-EV. Left panel (in green) shows pathways overrepresented by mRNAs detected by RNA sequencing of TEC-EV.
Right panel (in yellow) shows pathways overrepresented by proteins, detected by protein array in TEC-EV. Pathways relevant to inflammation are marked in pink. In
the intersection, there is a list of genes present in TEC-EV at both mRNA and protein levels.
by protein array, confirmed that TEC-EV carry mRNA and
proteins of genes relevant to inflammation (Figure 1, intersection
of the circles), such as interleukins and their receptors IL-
1a/b, IL1R2, IL6, IL10RB, IL11, IL6ST, IL13RA1, IL17R, IL7RA,
IL17RA, chemokines CCL2, CCL7, CCL8, CXCL8, CCL20,
growth factors TGF-a, TGF-β1, GDNF, VEGFa, M-CSF, CSF3,
IGFI, IGFII, CTF1, and others (MFG-E8, BAX, FADD, GLO1,
INHBA, IFNA/BR1, IFNGR1, and MIF). Using ELISA, we
further confirmed the enrichment of TEC-EV with TGF-β1,
IL-1β, IGF1, and VEGF.
Fluorescence-activated cell sorting analysis of TEC-EV
showed the surface representation of HLA class I, HLA G, CD47,
TLR4, VE-cadherin, CD44, CD63, CD81, ICAM, VCAM, and
CD31 proteins. Interestingly, TEC-EV were negative for CD45,
CD279, CD274, and HLA-DR (Supplementary Figure S2).
The molecular composition of TEC-EV suggests that
they are enriched with transcripts and proteins of different
immune pathways, and therefore can potentially regulate
immune reaction.
TEC-EV Activated PBMC and Stimulated
T Regulatory Cell Formation
To study the direct effect of TEC-EV on immune
cells, we stimulated PBMC (Table 1, recipient cell I,
Figure 2A) with the EV in serum-free medium, and
analyzed the changes in proliferation, differentiation, and
cytokine expression.
First, we demonstrated the uptake of TEC-EV by
PBMC. We added TEC-EV, labeled with PKH67GL
green fluorescent dye, to freshly isolated PBMC and
performed FACS analysis at different time points. TEC-
EV were absorbed faster by monocytes since after 3 h
more than 70% of these cells were fluorescent, while
lymphocytes even after 24 h were < 40% positive
(Supplementary Figure S3).
Interestingly, when we isolated monocytes and lymphocytes
from the total PBMC population to perform a separated
stimulation with TEC-EV, TEC-EV were hardly able to support
the viability of separated cells in serum-free medium, and we
did not see any changes in proliferation and cytokine secretion.
Therefore, we performed all following experiments on total
PBMC population.
Using FACS analysis, we compared the PBMC induced
with TEC-EV (PBMCind) with its unstimulated control
(ctrPBMC). The analysis showed that TEC-EV activated
monocytes, according to enhanced expression of CD14 and
CD69 (Supplementary Figure S4).
TEC-EV increased the expression of CD25, the marker
of proliferation, in both monocytes and lymphocytes
(fold change 3.5 for monocyte fraction, and 1.6 for
lymphocytes, p < 0.05, Supplementary Figure S4). These
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FIGURE 2 | PBMC stimulation with TEC-EV. (A) Scheme of the experiment: TEC- EV were isolated from TEC and used for the induction of PBMC (PBMCind). After
that, PBMCind and control non-stimulated PBMC (ctr PBMC) were analyzed by FACS, PCR, and ELISA. (B) Diagram of the PBMC cytokine secretion: IL-6, IFN-γ,
TNF-α, and IL-10, as well as TGF-β1 and VEGF are secreted significantly more by PBMCind than control PBMC. (C) Diagram of Treg formation by PBMCind.
(D) Representative FACS dot-plots of double-positive FoxP3+ (FITC) and CD25+ (PE) cells (up-right quarter, Q2), selected from CD4+ cells. (E) Diagram of MALAT1
expression in control PBMC and PBMCind. Data are represented as mean (SD), ∗p < 0.05 vs. PBMC, n = 15.
data suggest that TEC-EV stimulated the proliferation of both
cell types in PBMC.
We have also evaluated the role of TEC-EV on
the differentiation of the PBMC cells. Thus, TEC-
EV increased the expression of CD163 (fold change
2.6, p = 0.03) and CD206 (fold change 4.3, p = 0.05)
in monocyte fraction. These data suggest that TEC-
EV could induce differentiation of monocytes into
immunosuppressive macrophages type M2. Also, TEC-EV
significantly increased the expression of CD274 (PD-
L1) in monocyte fraction (fold change 4.4, p = 0.05,
Supplementary Figure S4).
ELISA analysis of cytokine expression in PBMCind
showed a significant increase of IFN-γ, TNF-α, IL-6, VEGF,
IL-10, and TGF-β1 expression relative to unstimulated
controls (Figure 2B). TGF-β1 plays an essential role in
u formation. Indeed, TEC-EV stimulation significantly
increased the population of Tregs (CD4+CD25+FoxP3+)
in PBMCind (fold change 3.96, p = 0.049) (Figures 2C,D).
We also showed that PBMC treatment with TEC-EV
increased the expression of MALAT1 in PBMCind (fold
change 2.7, p = 0.04, Figure 2E). Its increased expression
could be relevant for both M2-type differentiation of
macrophages and Treg formation (Masoumi et al.,
2019). All of these results suggest that TEC-EV induce
an immunosuppressive phenotype (formation of Treg
and CD206+, CD163+ monocytes) in PBMC via
influence on monocytes and lymphocyte proliferation
and differentiation.
PBMC Induced With TEC-EV Stimulate
Tumor Cell Proliferation and
Angiogenesis in vitro
To demonstrate the functional activity of the PBMC induced with
TEC-EV, we used the conditioned medium from PBMCind for
stimulation of tumor cells and TEC (Table 1, recipient cells II,
Figure 3A).
Conditioned medium from PBMCind enhanced the pro-
angiogenic properties of TEC in vitro (fold change 1.8,
p = 0.001 Figures 3B,C). That also correlated with the increased
production of VEGF, IL-6, and TGF-β1, the effectors of tumor
angiogenesis (Figure 2B). Moreover, conditioned medium from
PBMCind stimulated the proliferation of tumor cells (fold change
1.4, p = 0.04, Figure 3D).
According to these results, we suggested that stimulated
PBMC stimulated the growth of tumor mass and its angiogenesis.
TEC-EV Regulate Gene Expression in
ASCs
To study if TEC-EV induce immunosuppressive phenotype
in stromal cells, we analyzed the effect of TEC-EV on gene
regulation in ASCs directly (Table 1, recipient cells I), since
adipose tissue is present in close proximity of primary head
and neck tumors. For this reason, we induced ASCs with
TEC-EV (ASCind) for 24 and 48 h. We compared ASCind
and its unstimulated controls with the donor TEC cells. The
gene expression in each experiment was analyzed by RNA
sequencing (Figure 4) and was used to define gene expression
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FIGURE 3 | PBMCind regulated tumor cell growth and function. (A) Scheme of the experiment: conditioned medium from control PBMC and PBMCind were used
to stimulate TEC or tumor cells, then angiogenesis in vitro and proliferation were measured. As negative control were used TEC or tumor cells without any treatment
(no trtm). (B) Representative images of angiogenesis in vitro by TEC, stimulated with conditioned medium obtained from control PBMC or PBMCind. (C) Diagram of
the total length of vessel-like structures formed in vitro by TEC, stimulated with conditioned medium from control PBMC or PBMCind. (D) Diagram of stromal cell
proliferation. Data are represented as mean (SD), ∗p < 0.05 vs. CM PBMC CONTROL, n = 6.
signatures of acquired cancerization of ACS by the Bayesian
matrix factorization algorithm (CoGAPS) (Fertig et al., 2010).
The CoGAPS analysis demonstrated the coherent down-
regulation of a set of genes after the exposure of ACS to TEC-EV
(Figures 4B,C). Such downregulation correlated with the
overall nature of HNSCC, known for its tumor suppressor-
driven biology. This pattern contains genes that are highly
expressed in control ASCs, not expressed in TEC, and down-
regulated in ASCs after TEC-EV stimulation (Figure 4B).
These genes play a role in pathways involved in tumor immune
response (INFLAMMATORY_RESPONSE, COMPLEMENT,
IL6_JAK_STAT3_SIGNALING) and in fatty acid metabolism
pathway (FATTY_ACID_METABOLISM). These data suggest
immunosuppression and transdifferentiation of ASC after
TEC-EV induction.
ASCind-EV Activated PBMC and
Stimulated Tregs Formation
To demonstrate if tumorigenic induction could be passed
from TEC through ASCs to secondary cells by EV, we
collected EV released by ASCind (ASCind-EV) or control
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FIGURE 4 | TEC-EV influence on ASCs. (A) Scheme of the experiment: TEC-EV were used for the induction of ASC (ASCind). (B) Diagram of the relative expression
of genes from pattern 1, obtained after analysis of RNA sequencing data of ASCs stimulated with TEC-EV during 24 and 48 h. (C) Gene expression heatmap of the
inflammatory response group. ASCs at time point 0 h were taken as control (ASC ctr 0 h), also TEC were taken as control cells (TEC ctr). ASCs, induced during 24
and 48 h (ASCind 24 h and ASCind 48 h) were analyzed in parallel with non-stimulated ASCs at the same time points (ASC ctr 24 and ASC ctr 48 h respectively).
ASCs (ASC-EV) and used these EV for stimulation of
the recipient cells II (PBMC) (Table 1, recipient cells II,
Figure 5A).
The ASCind-EV and ASC-EV were characterized by protein
array. The protein level of CXCL2, CXCL5, FGF2, PGF, MMP1,
MMP3, CCL2, CCL7, S100A12, PRL, NID1, IL-10, TGF-α, and
TGF-β1-5 was increased in ASCind-EV relative to control ASC-
EV (Supplementary Figure S5A). Many of those proteins are
involved in tumor growth.
ASCind-EV had an increased level of lncRNA MALAT1
(Supplementary Figure S5B). ASCind-EV significantly
increased the secretion of IL-6 by and expression of
MALAT1 in PBMC (Figures 5B,C). This strongly
correlated with the increased expression of both IL-
6 and MALAT1 in PBMC after TEC-EV stimulation
(Figures 2B,E).
Functionally, PBMC adhesion on endothelium increased
after the stimulation with ASCind-EV (Figure 5D). Moreover,
ASCind-EV increase the formation of Treg relative to control
ASC-EV (Figure 5E and Supplementary Figure S6).
These findings suggest that ASC once stimulated with TEC-
EV could induce an immunosuppressive phenotype of PBMC
through the released ASCind-EV.
ASCind-EV Stimulate Tumor Cells
To study the effect of ASCind-EV on tumor stroma, we
stimulated tumor cells with the ASC-EV or ASCind-EV
and analyzed their biological activity (Table 1, recipient
cells II, Figure 6A). Tumor cell stimulation with ASCind-
EV led to a significant increase of TGF-β1 expression and
secretion (Figures 6B,C). Also, the expression of MALAT1
was significantly enhanced in tumor cells after the stimulation
with ASCind-EV (Figure 6B). This strongly correlates with the
increased expression of both TGF-β1 and MALAT1 in ASCind
(Supplementary Figure S5).
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FIGURE 5 | The influence of the ASCind on PBMC activity. (A) Scheme of the experiment: ASCind-EV were used for stimulation of PBMC, after that ELISA and
FACS analysis of the stimulated PBMC were performed. (B) Diagram of MALAT1 expression in PBMC stimulated with control ASC-EV or ASCind-EV respect to
non-treated PBMC (mean (SD), ∗p < 0.05 vs. ASC-EV, n = 8). As negative control were used PBMC without any treatment (no trtm). (C) Diagram of IL-6 secretion by
PBMC, stimulated or not with ASC-EV and ASCind-EV [mean (SD), ∗p < 0.05 vs. ASC-EV, n = 8]. (D) Diagram of the PBMC adhesion on endothelium after
stimulation with ASC-EV or ASCind-EV [mean (SD), ∗p < 0.05 vs. ASC-EV, n = 8]. (E) Diagram of Treg formation by PBMC, stimulated with ASC-EV or ASCind-EV
[mean (SD), ∗p < 0.05, n = 6].
Tumor cell invasion and adhesion on endothelium
(Figures 6D–F) were also increased, suggesting the increased
capacity of tumor cells to invade from circulation to tissue after
being stimulated with ASCind-EV.
These findings suggest that ASC once stimulated with TEC-
EV induce the migration of tumor cells from the bloodstream that
could be relevant to subsequent metastasis.
DISCUSSION
In our study, we showed that TEC-EV could transmit their
oncogenic signals, and this process represents a contagious
carcinogenesis. Unlike the metastatic spread of tumor cells, this
mechanism regulates tumor microenvironment and reprograms
immune cells to sustain tumor growth and progression.
In the present study for the first time, we showed the
pro-tumorigenic functions of the surrounding non-tumor
cells. Such data correlates with previous knowledge that
cancerous EV reprogram the immune and stromal cells of
the microenvironment to enhance tumor growth, angiogenesis,
migration, and tumor tolerance by immune cells (Grange et al.,
2015; Hoshino et al., 2015).
Extracellular vesicles, released from tumor cells, including
breast cancer (Lombardo et al., 2018), renal carcinoma
(Lopatina et al., 2019b), leukemia (Paggetti et al., 2015)
and others (Guo et al., 2019), participate in the formation of
tumor-promoting pre-metastatic niches (Hoshino et al., 2015).
Unfortunately, similar studies for HNSCC are limited. In this
work, we explored the role of cancer-derived EV on the local
microenvironment of HNSCC tissues and the mechanism of
spread of the pro-oncogenic signals. We have shown that this
effect is achieved through stromal and immune cells.
A short-time (24 h) stimulation of the recipient cells I
(PBMC or ASCs) with TEC-EV changed the gene expression
of these cells into pro-oncogenic direction. Thus, TEC-EV
regulate gene expression of ASC and decrease their immune
reaction. On the other hand, TEC-EV also activate PBMC,
regulate cytokine secretion, stimulate Treg cell formation, and
activate immunosuppression. Moreover, PBMC can get further
immunomodulated by EV from the induced ASCs. Therefore,
TEC acting through TEC-EV have both direct and indirect
effect on the immune system. This non-metastatic spread
of tumor signals to the healthy surrounding cells leads to
the carcinogenesis. Furthermore, stimulated PBMC and ASC
can carry out the induced pro-oncogenic signals to tumor
tissues, enhancing proliferation, adhesion, and invasion of tumor
cells, and angiogenesis of TEC. This process makes tumor-
surrounding immune and adipose cells function in favor of tumor
development and amplify the pro-oncogenic stimulus.
The immune system plays an important role in tumor
development. We have shown that EV are get absorbed mainly
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FIGURE 6 | The influence of the ASCind on tumor cell activity and functions. (A) Scheme of the experiment: ASCind-EV were used for stimulation of tumor cells,
after that tumor cell gene expression and secretory activity, adhesion, and invasion were measured. (B) Diagram of the MALAT1 and TGF-β1 gene expression in
tumor cells stimulated with ASC-EV or ASCind-EV [mean (SD), ∗p < 0.05, n = 6]. As negative control were used tumor cells without any treatment (no trtm).
(C) Diagram of TGF-β1 secretion by tumor cells stimulated with ASC-EV or ASCind-EV [mean (SD), ∗p < 0.05 vs. ASC-EV, n = 6]. (D) Representative images on
tumor cell invasion. Ability to invade into Matrigel was quantified by counting the number of invaded cells under a phase-contrast microscope. (E) Diagram on tumor
cell invasion. (F) Diagram of the tumor cell adhesion on endothelium [mean (SD), ∗p < 0.05 vs. ASC-EV, n = 6].
by monocytes, as well as by lymphocytes. These data is strongly
supported by the known internalization of EV by macrophages
(Imai et al., 2015). Moreover, our data strongly correlated with
the described role of different stromal non-tumor cells, such as
endothelial cells (Yu et al., 2010), fibroblasts (Knuchel et al.,
2015), mesenchymal stem cells (Lee and Hong, 2017), adipose-
derived stem cells (Wei et al., 2015), in the regulation of growth
and progression of tumors.
Obesity is considered to be another risk factor for cancer
progression (Abd Elmageed et al., 2014). Chronic inflammation
links obesity and tumor development, sharing plenty of
molecular mechanisms. Recent studies have shown that ASCs
can be easily induced into tumor direction (Razmkhah et al.,
2018). Moreover, HNSCC is often laid within close proximity
of adipose tissue (Tan et al., 2015; Gama et al., 2017). We
presume that the inflammatory status and biodiversity of each
sample of ASC did not affect the results of our study, since
we demonstrated the immunosuppressive effect of ASCind-
EV in comparison with control ASC-EV, collected from the
same ASC culture.
The immunosuppressive function of EV during cancer
formation was recently reported for head and neck cancer
development (Ludwig et al., 2017). Thus, EV from the plasma of
patients with the stages III/IV HNSCCs exhibit active immune
suppression functions through the synthesis of adenosine and
stimulation of Treg (Maybruck et al., 2017; Theodoraki et al.,
2018), by inducing apoptosis of CD8+ T cells and suppression
of CD4+ T-cell proliferation (Ludwig et al., 2017), by inducing
immunosuppressive phenotype of CD8+ cells (Maybruck et al.,
2017) and carrying immunosuppressive proteins, such as PD-
1, PD-L1, Fas, FasL, CTLA-4, TRAIL, CD73, COX2, TGFβ-LAP
(Ludwig et al., 2017). These data can explain a high speed of
HNSCC cancer formation and its high rate of cancer recurrence.
The recurrence rate for HNSCC is 25–48%, and sometimes up
to 67% and especially higher for the late-stages III–IV tumors
(Schwartz et al., 2000).
We delineated the genes expression signatures for the acquired
cancerization of ASCs, by the CoGAPS [Coordinated Gene
Activity in Pattern Sets, algorithm (Fertig et al., 2010)]. This
algorithm was applied to the gene expression time-course data
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of ASC stimulated with TEC-EV. CoGAPS was previously used
to successfully delineate the time-course data of therapeutic
response in breast and HNSCC (Hill et al., 2016; Stein-O’Brien
et al., 2018). In our case, it detected the critical role of
inflammatory response gene set to respond to TEC-EV stimuli
within 24 h (Figure 4).
Tumor and adjacent non-tumor cells in its microenvironment,
consisting of heterogenic malignant, stromal, and immune
cells, are found in continuous reciprocal communication.
The induction of non-tumor cells toward the oncogenic
direction by squamous tumor cells was first described as
field cancerization in 1953 (Slaughter et al., 1953). From that
time, the gene expression reciprocal regulation of the adjacent
tumor and non-tumor cells was demonstrated to almost all
types of cancer (Curtius et al., 2018). The recent single-
cell analysis of HNSCC showed that stromal and immune
cells had consistent gene expression across patients, whereas
malignant cells varied their expression signatures (Puram et al.,
2017). We showed how TEC could regulate gene expression
of PBMC and ASC through EV, making them favor tumor
development. In particular, we showed that TEC-EV increased
expression of TGF-β1 and MALAT1 in target cells. According
to the published data, TGF-β1 is involved not only in
immune suppression in tumor microenvironment (Takahashi
et al., 2017), but also promotes heterogeneity and cancer
stem cell formation (Oshimori et al., 2015) and epithelial-
mesenchymal transition (Horiguchi et al., 2012), supporting our
findings. Therefore, TEC-EV stimulated target cells to secret
TGF-β1 necessary for tumor cell differentiation and immune
surveillance escape.
The higher expression of MALAT1 was detected in PBMC
and in ASC-EV after direct stimulation with TEC-EV, as well
as in PBMC and tumor cells after stimulation with ASCind-
EV. MALAT1 was shown as a circulating biomarker of head
and neck cancer (He et al., 2017). TGF-β1 could activate the
transcription of MALAT1 (Wang et al., 2018), and MALAT1
in its turn could activate the transcription of LTBP3, a gene
that regulates the bioavailability of TGF-β (Li et al., 2014).
We have shown that TEC-EV could enhance the secretion
of both MALAT1 and TGF-β1 within ASCind-EV, and that
ASCind-EV could induce their expression by tumor cells, play a
role in Treg formation, and stimulate their immunosuppressive
activity. This transfer of MALAT1 could be one of the possible
molecular mechanisms that regulate tumor microenvironment.
Future studies are needed to understand those mechanisms.
In vitro we have shown the immunosuppressive effects
of EV derived from TEC of HNSCC, and transfer of these
effects through non-tumor cells, suggesting, that TEC-EV can
reprogram non-tumor cells into an oncogenic phenotype in short
time. These data need the in vivo confirmation, and we plan
to investigate the influence of TEC-EV on tumor growth and
tumor niche formation using laboratory in vivo models (Grange
et al., 2011). Such prospective work will also help us to define
the role of TEC-EV on the CoGAPS inflammatory cell pattern in
mice. Since EV, in general, have complex structures with highly
specific and diversified molecular composition, it is challenging
to identify the molecular mechanism of its action. We are going
to down-regulate the MALAT1 expression in TEC to see the
molecular changes in TEC-EV and their effect on Treg formation
and TGF-β1 production by target PBMC.
Overall, our data suggest that tumor tissues trigger many self-
promoting mechanisms that amplify the pro-oncogenic signals,
with a specific role of TEC, which line tumor blood vessels, and
their EV in this process. Moreover, our data suggest that TEC
might be essential targets for the development of cancer therapy.
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